Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) 是一家上市公司 属于 医疗保健 板块,经营于 制药 - 专科与仿制药 行业. 公司总部位于 Mexico City, DF, 墨西哥. 现任CEO为 Juan Marco Sparvieri.
GNMLF 拥有 IPO日期为 2012-05-04, 1,605 名全职员工, 在 Other OTC, 市值为 $1.05B.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.